India's Central Drugs Standard Control Organisation (CDSCO) flagged more than 100 medicine samples as 'not of standard quality' in its monthly alert for October, published on Monday. Several batches were also identified as suspected spurious. The list covered antibiotics, painkillers, antacids and vitamin supplements tested by central and state laboratories.

The regulator publishes the alert each month to identify batches that failed quality tests, such as dissolution, assay or labelling requirements. According to the CDSCO, a 'not of standard quality' finding applies only to the specific batch tested. It does not mean other batches of the same product are defective. Manufacturers named on the list are expected to recall the affected stock, and state drug controllers are responsible for enforcement.

The alert came days after the Union Ministry of Health and Family Welfare publicised two draft notifications aimed at tightening oversight of the pharmaceutical supply chain. The first, G.S.R. 983(E), dated 6 November and publicised on 19 November, would add antimicrobials to the definition of 'new drug' under the New Drugs and Clinical Trials Rules, 2019. Manufacturers would then need prior approval from the national regulator. The second, G.S.R. 987(E), dated 2 November, would amend the Drugs Rules, 1945 to create a separate wholesale licence for bulk drugs.

India's drug quality regime has faced intense pressure since children died in Madhya Pradesh in 2025 after taking cough syrup contaminated with diethylene glycol. That episode prompted the CDSCO to step up risk-based inspections of manufacturing units.

Small and medium-sized firms have also faced pressure to comply with the revised Schedule M good manufacturing practice standards. The regulator has said the monthly alerts are intended to make quality failures visible to doctors, pharmacists and patients.

The inclusion of antibiotics among the failed samples is likely to strengthen the ministry's case for tighter control of antimicrobial manufacturing. Substandard antibiotics can deliver sub-therapeutic doses that encourage drug resistance, a risk highlighted by the World Health Organization. Public comment on the antimicrobial draft remains open until mid-December, after which the ministry can finalise the rules.